Psilocybin Research

Psilocybin Research By Topic

The following list provides a broad overview of the current body of peer-reviewed scientific research on psilocybin, organized by subject area. While it includes many of the published studies available to date, it is not intended to be exhaustive, as research in this field continues to evolve. This resource will be updated periodically as additional peer-reviewed publications become available.

A

Addiction

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. Bogenschutz MP, Ross S, Bhatt S, et al. JAMA Psychiatry. 2022. https://doi.org/10.1001/jamapsychiatry.2022.2096

Psilocybin or Nicotine Patch for Smoking Cessation. Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A. JAMA Netw Open. 2026. https://doi.org/10.1001/jamanetworkopen.2026.0972

Alcohol Use Disorder

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder. Urban MM, Zillich L, Rieser NM, et al. Transl Psychiatry. 2026. https://doi.org/10.1038/s41398-026-03961-3

Alzheimer’s

Psilocybin for the treatment of Alzheimer’s disease. Zheng S, Ma R, Yang Y, Li G. Frontiers in Neuroscience. 2024. https://doi.org/10.3389/fnins.2024.1420601

Psychedelics as a Treatment for Alzheimer’s Disease Dementia. Vann Jones SA, O’Kelly A. Frontiers in Synaptic Neuroscience. 2020. https://doi.org/10.3389/fnsyn.2020.00034

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report. Lago M, Cerveira M, Simonet JX. Frontiers in Neuroscience. 2026. https://doi.org/10.3389/fnins.2026.1813281

Anorexia Nervosa

Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials. Bevione F, Lacidogna MC, Lavalle R, Abbate Daga G, Preti A. Eating and Weight Disorders. 2025. https://doi.org/10.1007/s40519-025-01771-y

Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Conn K, Milton LK, Huang K, et al. Molecular Psychiatry. 2024. https://doi.org/10.1038/s41380-024-02575-9

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa. Peck SK, Brewerton TD, Fisher H, et al. Journal of Eating Disorders. 2025. https://doi.org/10.1186/s40337-025-01274-2

Anti-Aging

Psilocybin treatment extends cellular lifespan and improves survival of aged mice. Kato K, Kleinhenz JM, Shin YJ, et al. npj Aging. 2025. https://doi.org/10.1038/s41514-025-00244-x

Antidepressants

Concomitant use of antidepressants and classic psychedelics: A scoping review. Tap SC, Thomas K, Páleníček T, et al. Journal of Psychopharmacology. 2025. https://doi.org/10.1177/02698811251368360

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. PNAS. 2021. https://doi.org/10.1073/pnas.2022489118

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions. Williams ZJ, Barnett H, Szigeti B. JAMA Psychiatry. 2026. https://doi.org/10.1001/jamapsychiatry.2025.4809

Anxiety

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Rootman JM, Kryskow P, Harvey K, et al. Scientific Reports. 2021. https://doi.org/10.1038/s41598-021-01811-4

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Frontiers in Psychiatry. 2019. https://doi.org/10.3389/fpsyt.2019.00672

Attention Deficit Hyperactivity Disorder (ADHD)

Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study. Haijen ECHM, Hurks PPM, Kuypers KPC. Neuroscience Applied. 2022. https://doi.org/10.1016/j.nsa.2022.101012

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN. NeuroImage. 2020. https://doi.org/10.1016/j.neuroimage.2020.116980

Auto-Immune Diseases

Potential Benefits of Psilocybin for Lupus Pain: A Case Report. Gonzales SAB, Alexopoulos C, Arkfeld DG. Current Rheumatology Reviews. 2024. https://doi.org/10.2174/1573397119666230904150750

Psychedelic control of neuroimmune interactions governing fear. Chung EN, Lee J, Polonio CM, et al. Nature. 2025. https://doi.org/10.1038/s41586-025-08880-9

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Mason NL, Szabo A, Kuypers KPC, et al. Brain, Behavior, and Immunity. 2023. https://doi.org/10.1016/j.bbi.2023.09.004

Psychedelics as a novel approach to treating autoimmune conditions. Thompson C, Szabo A. Immunology Letters. 2020. https://doi.org/10.1016/j.imlet.2020.10.001

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. Kinderlehrer DA. International Medical Case Reports Journal. 2023. https://doi.org/10.2147/IMCRJ.S395342

B

Bipolar Disorder

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption. Morton E, Sakai K, Ashtari A, et al. Journal of Psychopharmacology. 2023. https://doi.org/10.1177/02698811221131997

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder. Meshkat S, Kaczmarek E, Doyle Z, et al. Psychedelic Medicine. 2025. https://doi.org/10.1089/psymed.2024.0032

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. Aaronson ST, van der Vaart A, Miller T, et al. JAMA Psychiatry. 2024. https://doi.org/10.1001/jamapsychiatry.2023.4685

Borderline Personality Disorder

Psychedelics as a potential treatment for borderline personality disorder: A narrative review. Artna E, Sandhu G, Chisamore N, et al. Psychiatry Research. 2026. https://doi.org/10.1016/j.psychres.2026.117152

C

Creativity

Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials. Prochazkova L, Marschall J, van Elk M, et al. Neuropharmacology. 2026. https://doi.org/10.1016/j.neuropharm.2025.110732

Psilocybin’s effects on cognition and creativity: A scoping review. Bonnieux JN, VanderZwaag B, Premji Z, Garcia-Romeu A, Garcia-Barrera MA. Journal of Psychopharmacology. 2023. https://doi.org/10.1177/02698811231179801

Spontaneous and deliberate creative cognition during and after psilocybin exposure. Mason NL, Kuypers KPC, Reckweg JT, et al. Translational Psychiatry. 2021. https://doi.org/10.1038/s41398-021-01335-5

Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. Mason NL, Mischler E, Uthaug MV, Kuypers KPC. Journal of Psychoactive Drugs. 2019. https://doi.org/10.1080/02791072.2019.1580804

D

Dementia

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Haniff ZR, Bocharova M, Mantingh T, et al. Pharmacology & Therapeutics. 2024. https://doi.org/10.1016/j.pharmthera.2024.108641

Psychedelics as a Treatment for Alzheimer’s Disease Dementia. Vann Jones SA, O’Kelly A. Frontiers in Synaptic Neuroscience. 2020. https://doi.org/10.3389/fnsyn.2020.00034

Depression

Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder. Rasheed S, Arif R, Raza AA, Samadi A. Annals of Medicine and Surgery. 2025. https://doi.org/10.1097/MS9.0000000000004349

Increased global integration in the brain after psilocybin therapy for depression. Daws RE, Timmermann C, Giribaldi B, et al. Nature Medicine. 2022. https://doi.org/10.1038/s41591-022-01744-z

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial. Mertens LJ, Betzler F, Brand M, et al. Psychotherapy and Psychosomatics. 2026. https://doi.org/10.1159/000552272

Psilocybin for major depressive disorder: a systematic review of randomized controlled studies. Li LJ, Mo Y, Shi ZM, et al. Frontiers in Psychiatry. 2024. https://doi.org/10.3389/fpsyt.2024.1416420

What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Castro Santos H, Gama Marques J. Porto Biomedical Journal. 2021. https://doi.org/10.1097/j.pbj.0000000000000128

Dissociation

E

Eating Disorders

Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design. Koning E, Chaves C, Kirkpatrick RH, Brietzke E. Journal of Eating Disorders. 2024. https://doi.org/10.1186/s40337-024-01185-8

Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence. Koning E, Brietzke E. Trends in Psychiatry and Psychotherapy. 2024. https://doi.org/10.47626/2237-6089-2022-0597

Epilepsy

Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors. Balabandian M, Manavi MA, Lesani A, et al. Pharmacology Research & Perspectives. 2025. https://doi.org/10.1002/prp2.70079

Prevalence and associations of classic psychedelic-related seizures in a population-based sample. Simonsson O, Goldberg SB, Chambers R, et al. Drug and Alcohol Dependence. 2022. https://doi.org/10.1016/j.drugalcdep.2022.109586

Psychedelics, epilepsy, and seizures: a review. Freidel N, Kreuder L, Rabinovitch BS, et al. Frontiers in Pharmacology. 2024. https://doi.org/10.3389/fphar.2023.1326815

F

Fibromyalgia

Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. Bonnelle V, Smith WJ, Mason NL, et al. British Journal of Pain. 2022. https://doi.org/10.1177/20494637221114962

Microdosing psilocybin for chronic pain: a case series. Lyes M, Yang KH, Castellanos J, Furnish T. Pain. 2023. https://doi.org/10.1097/j.pain.0000000000002778

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Aday JS, McAfee J, Conroy DA, et al. Frontiers in Pain Research. 2025. https://doi.org/10.3389/fpain.2025.1527783

Psilocybin and chronic neuropathic pain: a systematic review. Jevotovsky DS, Chopra H, Pak DJ, et al. Regional Anesthesia & Pain Medicine. 2025. https://doi.org/10.1136/rapm-2024-105532

Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action.” Bornemann J, Close JB, Ahmad K, et al. Frontiers in Psychiatry. 2024. https://doi.org/10.3389/fpsyt.2024.1320780

G

Gastrointestinal Issues

Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder. Gattuso JJ, Kong G, Bezcioglu B, et al. Neuropharmacology. 2025. https://doi.org/10.1016/j.neuropharm.2025.110648

Microbiome: The Next Frontier in Psychedelic Renaissance. Kargbo RB. Journal of Xenobiotics. 2023. https://doi.org/10.3390/jox13030025

Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue. Robinson GI, Li D, Wang B, et al. Life. 2023. https://doi.org/10.3390/life13122345

Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome. Mauney E, King F, Burton-Murray H, Kuo B. Journal of Clinical Gastroenterology. 2025. https://doi.org/10.1097/MCG.0000000000002149

Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications. Wang X, Jun F, Lin C, Wang X. ACS Chemical Neuroscience. 2025. https://doi.org/10.1021/acschemneuro.5c00418

Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. Kelly JR, Clarke G, Harkin A, et al. International Journal of Clinical and Health Psychology. 2023. https://doi.org/10.1016/j.ijchp.2022.100349

H

Hashimoto’s Disease

See Auto-Immune Diseases

Headaches

A systematic review to assess the use of psilocybin in the treatment of headaches. Bhanot S, Lin MCQ, Bains S, Monroe A, Tsang VWL. European Psychiatry. 2023. https://doi.org/10.1192/j.eurpsy.2023.1286

Lifetime classic psychedelic use and headaches: A cross-sectional study. Bjurenfalk Z, Cosmo A, Simonsson O, Ran C. Journal of Psychopharmacology. 2025. https://doi.org/10.1177/02698811251324372

Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Schindler EAD, Sewell RA, Gottschalk CH, et al. Journal of the Neurological Sciences. 2024. https://doi.org/10.1016/j.jns.2024.122993

Hormones

Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy. Ekoh F, Rerrie S, Angud J, Mirabelli E. Psychoactives. 2025. https://doi.org/10.3390/psychoactives4040039

Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. Gukasyan N, Narayan SK. Journal of Psychoactive Drugs. 2024. https://doi.org/10.1080/02791072.2022.2157350

I

Inflammation

LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice. Robinson GI, Gerasymchuk M, Zanikov T, et al. Pharmaceuticals. 2025. https://doi.org/10.3390/ph18040451

J

K

L

Lupus

Potential Benefits of Psilocybin for Lupus Pain: A Case Report. Gonzales SAB, Alexopoulos C, Arkfeld DG. Current Rheumatology Reviews. 2024. https://doi.org/10.2174/1573397119666230904150750

Lyme Disease

Pilot study of psilocybin in patients with post-treatment lyme disease. Garcia-Romeu A, Naudé GP, Rebman AW, et al. Scientific Reports. 2026. https://doi.org/10.1038/s41598-026-38091-9

M

Memory

Impact of psilocybin on cognitive function: A systematic review. Meshkat S, Tello-Gerez TJ, Gholaminezhad F, et al. Psychiatry and Clinical Neurosciences. 2024. https://doi.org/10.1111/pcn.13741

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models. Adeyinka D, Forsyth D, Currie S, Faraone N. Frontiers in Systems Neuroscience. 2025. https://doi.org/10.3389/fnsys.2025.1585367

The acute effects of classic psychedelics on memory in humans. Healy CJ. Psychopharmacology. 2021. https://doi.org/10.1007/s00213-020-05756-w

The Effect of Psilocybe cubensis on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress. Ghaffarzadegan R, Karimi M, Hedayatjoo B, et al. Journal of Psychoactive Drugs. 2026. https://doi.org/10.1080/02791072.2024.2428241

Menopause

Estrogen-immuno-neuromodulation disorders in menopausal depression. Zhang Y, Tan X, Tang C. Journal of Neuroinflammation. 2024. https://doi.org/10.1186/s12974-024-03152-1

Microdosing Psychedelics for Menopausal Symptoms Easing Brain Fog, Low Mood, and Cognitive Decline. Pennington A. In8Vitality. 2023. SEE ARTICLE HERE

Microdosing

Microdosing psilocybin for chronic pain: a case series. Lyes M, Yang KH, Castellanos J, Furnish T. Pain. 2023. https://doi.org/10.1097/j.pain.0000000000002778

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity. Kinderlehrer D. Neuropsychiatric Disease and Treatment. 2025. https://doi.org/10.2147/NDT.S500337

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Rootman JM, Kiraga M, Kryskow P, et al. Scientific Reports. 2022. https://doi.org/10.1038/s41598-022-14512-3

Migraines

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Schindler EAD, Sewell RA, Gottschalk CH, et al. Neurotherapeutics. 2021. https://doi.org/10.1007/s13311-020-00962-y

Mood

Emotions and brain function are altered up to one month after a single high dose of psilocybin. Barrett FS, Doss MK, Sepeda ND, et al. Scientific Reports. 2020. https://doi.org/10.1038/s41598-020-59282-y

The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry. Soylemez KK, de Boo EM, Susuzlu A, Lusher J. Journal of Personalized Medicine. 2025. https://doi.org/10.3390/jpm15100450

N

Neuropathy

Microdosing psilocybin for chronic pain: a case series. Lyes M, Yang KH, Castellanos J, Furnish T. Pain. 2023. https://doi.org/10.1097/j.pain.0000000000002778

Effect of acute psilocybin on thermal and neuropathic pain in rodents. Canul L, Nguyen V, Inserra A, et al. International Journal of Neuropsychopharmacology. 2025. https://doi.org/10.1093/ijnp/pyae059.091

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. Askey T, Allen-Ross D, Luzyanin D, et al. Communications Biology. 2026. https://doi.org/10.1038/s42003-026-10065-7

Psilocybin and chronic neuropathic pain: a systematic review. Jevotovsky DS, Chopra H, Pak DJ, et al. Regional Anesthesia and Pain Medicine. 2025. https://doi.org/10.1136/rapm-2024-105532

Psychedelics; an untapped therapeutic niche: a narrative review in the future of cancer pain management. Yap MMC, Omer YMA, Cheng YX. Medicine in Drug Discovery. 2026. https://doi.org/10.1016/j.medidd.2026.100256

O

Obsessive Compulsive Disorder

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. Moreno FA, Allen KE, Wiegand CB, et al. Journal of Psychopharmacology. 2026. https://doi.org/10.1177/02698811261424214

Psilocybin and Obsessive Compulsive Disorder. Wilcox JA. Journal of Psychoactive Drugs. 2014. https://doi.org/10.1080/02791072.2014.963754

Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Owe-Larsson M, Kamińska K, Buchalska B, Mirowska-Guzel D, Cudnoch-Jędrzejewska A. Pharmacological Reports. 2024. https://doi.org/10.1007/s43440-024-00633-1

Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms. Collins HM. International Journal of Neuropsychopharmacology. 2024. https://doi.org/10.1093/ijnp/pyae057

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Journal of Clinical Psychiatry. 2006. https://doi.org/10.4088/jcp.v67n1110

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Pellegrini L, Fineberg NA, O’Connor S, et al. Comprehensive Psychiatry. 2025. https://doi.org/10.1016/j.comppsych.2025.152619

P

Pain Management

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Zia FZ, Baumann MH, Belouin S, et al. Neuropharmacology. 2023. https://doi.org/10.1016/j.neuropharm.2023.109528

Exploring the Therapeutic Potential of Psychedelics in Chronic Pain Management: A New Frontier in Medicine. Lin C, Wang X, Wang X. Neuroscience Bulletin. 2025. https://doi.org/10.1007/s12264-025-01351-1

IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain. Koseli E, Buzzi B, Honaker T, et al. Pharmacological Research. 2025. https://doi.org/10.1016/j.phrs.2025.107699

Microdosing psilocybin for chronic pain: a case series. Lyes M, Yang KH, Castellanos J, Furnish T. Pain. 2023. https://doi.org/10.1097/j.pain.0000000000002778

Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists? Natoli S, Cuomo A, Marchesini M, et al. Medical Sciences. 2025. https://doi.org/10.3390/medsci13040277

Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain. Hammo A, Wisser S, Cichon J. Nature Neuroscience. 2025. https://doi.org/10.1038/s41593-025-02068-0

Parkinson’s Disease

Comparing psilocybin to metformin as neuroprotective agents against Parkinson’s dementia: A systematic review of evidence and efficacy. Ordovich-Clarkson RD, Jabbour M, Pelayo DA, et al. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2025. https://doi.org/10.1016/j.pnpbp.2024.111155

Psilocybin-assisted psychotherapy for Parkinson’s disease without depression: A case-report. Fleury V, Tomkova E, Catalano Chiuvé S, Penzenstadler L. Journal of Parkinson’s Disease. 2025. https://doi.org/10.1177/1877718X241312604

Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial. Bradley ER, Sakai K, Fernandes-Osterhold G, et al. Neuropsychopharmacology. 2025. https://doi.org/10.1038/s41386-025-02097-0

Treatment with psychedelics: potential benefits in Parkinson’s disease. Penzenstadler L, Baudois S, Lingenberg A, et al. Revue Medicale Suisse. 2025. https://doi.org/10.53738/REVMED.2025.21.915.47180

Post-Traumatic Stress Disorder (PTSD)

Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework. Modlin NL, Williamson V, Maggio C, et al. Therapeutic Advances in Psychopharmacology. 2025. https://doi.org/10.1177/20451253251342319

Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings. Calnan M, Blest-Hopley G, Busch C, et al. Brain and Behavior. 2025. https://doi.org/10.1002/brb3.70660

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment. Modlin NL, Williamson V, Goodwin GM, et al. EClinicalMedicine. 2025. https://doi.org/10.1016/j.eclinm.2025.103692

Mechanisms of psilocybin on the treatment of posttraumatic stress disorder. Choi C, Johnson DE, Chen-Li D, Rosenblat J. Journal of Psychopharmacology. 2026. https://doi.org/10.1177/02698811241286771

Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions. Bhatt SR, Armstrong M, Parker T, et al. Frontiers in Pharmacology. 2022. https://doi.org/10.3389/fphar.2022.905753

PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin. Folorunsho IL, Harry NM, Obiajunwa C, et al. Journal of Advances in Medicine and Medical Research. 2024. https://doi.org/10.9734/jammr/2024/v36i85525

Reviewing the Potential of Psychedelics for the Treatment of PTSD. Krediet E, Bostoen T, Breeksema J, et al. International Journal of Neuropsychopharmacology. 2020. https://doi.org/10.1093/ijnp/pyaa018

Pre-Menstrual Dysphoric Disorder (PMDD)

Psilocybin

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Mason NL, Kuypers KPC, Müller F, et al. Neuropsychopharmacology. 2020. https://doi.org/10.1038/s41386-020-0718-8

Molecular insights into psychedelic drug action. Slocum ST, DiBerto JF, Roth BL. Journal of Neurochemistry. 2022. https://doi.org/10.1111/jnc.15540

Psilocybin desynchronizes the human brain. Siegel JS, Subramanian S, Perry D, et al. Nature. 2024. https://doi.org/10.1038/s41586-024-07624-5

The Emergence of Psilocybin in Psychiatry and Neuroscience. Omidian H, Omidian A. Pharmaceuticals. 2025. https://doi.org/10.3390/ph18040555

Psychoplastogens

Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. Olson DE. Journal of Experimental Neuroscience. 2018. https://doi.org/10.1177/1179069518800508

Q

R

S

Seizures

Psychedelics, epilepsy, and seizures: a review. Freidel N, Kreuder L, Rabinovitch BS, et al. Frontiers in Pharmacology. 2024. https://doi.org/10.3389/fphar.2023.1326815

Serotonin

Serotonin and brain function: a tale of two receptors. Carhart-Harris RL, Nutt DJ. Journal of Psychopharmacology. 2017. https://doi.org/10.1177/0269881117725915

The Key Role of Intracellular 5-HT2A Receptors: A Turning Point in Psychedelic Research? Sapienza J. Psychoactives. 2023. https://doi.org/10.3390/psychoactives2040018

Sleep

Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache. Brendstrup-Brix K, Ozenne B, Fisher PM, et al. Journal of Psychopharmacology. 2026. https://doi.org/10.1177/02698811261449380

Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. Reid MJ, Kettner H, Blanken TF, Weiss B, Carhart-Harris R. Current Psychiatry Reports. 2024. https://doi.org/10.1007/s11920-024-01539-8

The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action. Dudysová D, Janků K, Šmotek M, et al. Frontiers in Pharmacology. 2020. https://doi.org/10.3389/fphar.2020.602590

The Intersection of Psychedelics and Sleep: Exploring the Impacts on Sleep Architecture, Dream States, and Therapeutic Implications. Zhai H, Wang H, Li H, Wang X. ACS Pharmacology & Translational Science. 2025. https://doi.org/10.1021/acsptsci.5c00234

Smoking

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A. JAMA Netw Open. 2026. https://doi.org/10.1001/jamanetworkopen.2026.0972

Substance Use Disorders

Suicidal Ideation

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. Ross S, Agin-Liebes G, Lo S, et al. ACS Pharmacology & Translational Science. 2021. https://doi.org/10.1021/acsptsci.1c00020

Psilocybin, psychological distress, and suicidality. Hendricks PS, Johnson MW, Griffiths RR. Journal of Psychopharmacology. 2015. https://doi.org/10.1177/0269881115598338

The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses. Zhang Y, Yang L, Zhang Q, et al. Translational Psychiatry. 2025. https://doi.org/10.1038/s41398-025-03410-7

T

Tinnitus

Current status and future prospects of research on psilocybin’s regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus. Lu S, Zhang Z, Xue X, et al. Hearing Research. 2026. https://doi.org/10.1016/j.heares.2026.109701

Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex. Brockett AT, Francis NA. Journal of Neurophysiology. 2024. https://doi.org/10.1152/jn.00124.2024

Psilocybin prevents habituation to familiar stimuli and preserves sensitivity to sound following repeated stimulation in mouse primary auditory cortex. Lane CP, Tarka VM, Valentin O, et al. bioRxiv. 2024. https://doi.org/10.1101/2024.09.27.614985

Trauma

Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment. Healy CJ, Lee KA, D’Andrea W. Chronic Stress. 2021. https://doi.org/10.1177/24705470211029881

Treatment Resistant Depression

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Scientific Reports. 2017. https://doi.org/10.1038/s41598-017-13282-7

Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats. Wang Z, Robbins B, Zhuang R, et al. Scientific Reports. 2025. https://doi.org/10.1038/s41598-025-03383-z

Self-administration of Psilocybin in the Setting of Treatment-resistant Depression. Lyons A. Innovations in Clinical Neuroscience. 2022. SEE ARTICLE HERE

Psilocybin Research